The implant is engineered to offer PER-001’s sustained release, aiming for a “convenient” dosing frequency of every six ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...